Milnacipran Eg (Milnacipran Hydrochloride)

Milnacipran acts on the serotonin‑norepinephrine pathway and is used in specific psychiatric and pain‑related conditions.

• Major depressive disorder: alleviates depressive symptoms by enhancing serotonergic and noradrenergic neurotransmission.
• Fibromyalgia: reduces widespread pain and improves functional capacity in adults with fibromyalgia.
• Co‑morbid depression in fibromyalgia: helps improve mood symptoms in patients experiencing depression alongside fibromyalgia.

• Milnacipran inhibits the presynaptic reuptake of serotonin (5‑HT) and norepinephrine (NE) by blocking their respective transporters (SERT and NET). This raises extracellular concentrations of both neurotransmitters in central nervous system synapses, enhancing neurotransmission in pathways involved in mood regulation and pain modulation. The dual inhibition distinguishes it from selective serotonin reuptake inhibitors and contributes to its therapeutic effects in depression and fibromyalgia.

Milnacipran may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Headache: transient cranial pain.
• Dry mouth: reduced salivation.
• Insomnia: difficulty initiating or maintaining sleep.

Serious or Rare Side Effects

• Hypertension: elevated blood pressure requiring monitoring.
• Serotonin syndrome: potentially life‑threatening condition when combined with other serotonergic agents.
• Severe allergic reaction: rash, angioedema, or anaphylaxis.

When prescribing Milnacipran, clinicians should consider several safety measures.

• Cardiovascular assessment: monitor blood pressure and heart rate regularly.
• Hepatic function: evaluate liver enzymes before initiating therapy.
• Psychiatric monitoring: observe for emergence of suicidal thoughts or mood changes.
• Drug interactions: avoid concomitant use with MAO inhibitors and other serotonergic agents.
• Pregnancy and lactation: use only if potential benefit justifies potential risk; discuss with healthcare provider.
• Store at ambient temperature: keep below 25°C in original packaging, protect from moisture and light.

Milnacipran can interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis and serotonin syndrome.
• Other serotonergic drugs (e.g., SSRIs, tramadol): increased risk of serotonin syndrome.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise milnacipran plasma levels.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin): may reduce drug exposure.
• Antihypertensive agents: additive blood pressure‑lowering effect.
• Diuretics: potential for enhanced orthostatic hypotension.